MiNK Therapeutics (INKT) Competitors $14.98 +0.82 (+5.79%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$14.70 -0.29 (-1.90%) As of 10/24/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT vs. FTFT, RENB, CRBU, OGI, ALTS, LFCR, AVIR, SGMT, CRBP, and HRTXShould you be buying MiNK Therapeutics stock or one of its competitors? The main competitors of MiNK Therapeutics include Future FinTech Group (FTFT), Lunai Bioworks (RENB), Caribou Biosciences (CRBU), Organigram Global (OGI), ALT5 Sigma (ALTS), Lifecore Biomedical (LFCR), Atea Pharmaceuticals (AVIR), Sagimet Biosciences (SGMT), Corbus Pharmaceuticals (CRBP), and Heron Therapeutics (HRTX). MiNK Therapeutics vs. Its Competitors Future FinTech Group Lunai Bioworks Caribou Biosciences Organigram Global ALT5 Sigma Lifecore Biomedical Atea Pharmaceuticals Sagimet Biosciences Corbus Pharmaceuticals Heron Therapeutics Future FinTech Group (NASDAQ:FTFT) and MiNK Therapeutics (NASDAQ:INKT) are related small-cap companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership. Which has more volatility & risk, FTFT or INKT? Future FinTech Group has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Do analysts prefer FTFT or INKT? MiNK Therapeutics has a consensus target price of $37.50, indicating a potential upside of 150.33%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe MiNK Therapeutics is more favorable than Future FinTech Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Future FinTech Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00MiNK Therapeutics 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50 Do insiders & institutionals have more ownership in FTFT or INKT? 0.2% of Future FinTech Group shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 0.9% of Future FinTech Group shares are owned by company insiders. Comparatively, 22.5% of MiNK Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer FTFT or INKT? In the previous week, MiNK Therapeutics had 3 more articles in the media than Future FinTech Group. MarketBeat recorded 4 mentions for MiNK Therapeutics and 1 mentions for Future FinTech Group. Future FinTech Group's average media sentiment score of 1.89 beat MiNK Therapeutics' score of 1.16 indicating that Future FinTech Group is being referred to more favorably in the media. Company Overall Sentiment Future FinTech Group Very Positive MiNK Therapeutics Positive Which has better earnings & valuation, FTFT or INKT? MiNK Therapeutics has lower revenue, but higher earnings than Future FinTech Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFuture FinTech Group$2.16M19.78-$32.96MN/AN/AMiNK TherapeuticsN/AN/A-$9.51M-$2.88-5.20 Is FTFT or INKT more profitable? MiNK Therapeutics' return on equity of 0.00% beat Future FinTech Group's return on equity.Company Net Margins Return on Equity Return on Assets Future FinTech GroupN/A -347.16% -200.95% MiNK Therapeutics N/A N/A -227.24% SummaryMiNK Therapeutics beats Future FinTech Group on 9 of the 13 factors compared between the two stocks. Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INKT vs. The Competition Export to ExcelMetricMiNK TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$67.73M$3.46B$6.21B$10.81BDividend YieldN/A2.28%5.72%4.80%P/E Ratio-5.2028.5131.6030.98Price / SalesN/A497.40595.06133.64Price / CashN/A46.9537.2561.86Price / Book-3.0310.4012.056.61Net Income-$9.51M-$52.83M$3.34B$277.10M7 Day Performance7.00%2.10%1.94%2.57%1 Month Performance7.31%10.17%6.88%3.20%1 Year Performance111.37%16.57%56.06%33.22% MiNK Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INKTMiNK Therapeutics2.8644 of 5 stars$14.98+5.8%$37.50+150.3%+113.4%$67.73MN/A-5.2030Positive NewsAnalyst ForecastFTFTFuture FinTech Group1.5179 of 5 stars$2.06-2.8%N/A-34.6%$41.51M$2.16M0.0070Positive NewsRENBLunai Bioworks0.1779 of 5 stars$1.54+21.7%N/A-69.8%$250.24MN/A-2.0020Gap DownCRBUCaribou Biosciences2.819 of 5 stars$2.63-1.5%$6.67+153.5%+40.7%$244.91M$9.99M-1.48100News CoveragePositive NewsAnalyst ForecastOGIOrganigram Global0.8494 of 5 stars$1.82-3.7%N/A-5.4%$244.50M$117.47M36.41860Positive NewsAnalyst ForecastALTSALT5 Sigma0.3286 of 5 stars$1.95-11.0%N/A-22.5%$243.65M$12.53M0.00170Gap UpHigh Trading VolumeLFCRLifecore Biomedical1.4506 of 5 stars$6.49-0.6%$8.00+23.3%+23.4%$243.18M$128.87M-4.95690Analyst ForecastAVIRAtea Pharmaceuticals2.2696 of 5 stars$3.06-1.9%$6.00+96.1%-4.2%$242.84MN/A-1.9070News CoverageAnalyst ForecastSGMTSagimet Biosciences3.2029 of 5 stars$7.36-2.5%$25.67+248.7%+63.5%$239.35M$2M-4.028News CoverageAnalyst ForecastGap UpCRBPCorbus Pharmaceuticals4.2349 of 5 stars$19.32+1.4%$45.43+135.1%+3.5%$236.86MN/A-4.0640News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeHRTXHeron Therapeutics4.0676 of 5 stars$1.29-0.8%$4.50+248.8%-35.1%$236.48M$144.29M-64.50300News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Future FinTech Group Competitors Lunai Bioworks Competitors Caribou Biosciences Competitors Organigram Global Competitors ALT5 Sigma Competitors Lifecore Biomedical Competitors Atea Pharmaceuticals Competitors Sagimet Biosciences Competitors Corbus Pharmaceuticals Competitors Heron Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INKT) was last updated on 10/26/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallyMissed Bitcoin when it was $100? You’re not alone. Crypto runs in cycles—and the next one is already underw...Crypto 101 Media | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredBuy the dip? Here’s my #1 gold stock“The most obvious opportunity in gold stocks I’ve seen in my career” While everyone is distracted by gold’s...Golden Portfolio | SponsoredThe strategy that wins no matter where the market goesJoel and Adam have built a crypto trading system with a 93% win rate — even through volatile, sideways markets...Crypto Swap Profits | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | SponsoredElon Musk is on the lineElon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
